ArticleJournal of the American Heart Association2025
Clinical Usefulness of Left Ventricular Global Longitudinal Strain as a Predictor of Prognosis in Patients With Acute Ischemic Stroke (GLS-STROKE Study).
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic role of left ventricular global longitudinal strain (LV-GLS) in acute ischemic stroke (AIS) remains unexplored despite its established value in cardiovascular conditions. We aimed to investigate the prognostic value of LV-GLS in patients with AIS.
methodsIn this prospective cohort study, 698 patients with AIS (mean age, 67.6±13.8 years; 60.2% men) underwent transthoracic echocardiography using speckle-tracking to measure LV-GLS within 7 days of admission. The primary end points included all-cause death and recurrent ischemic stroke, with a 3-month modified Rankin Scale score ≥3 considered a poor outcome.
resultsOver a median follow-up of 593 days, the primary end point occurred in 65 patients (9.3%), with significant differences in LV-GLS between those reaching the end point (16.3%) and the others (19.1%;
conclusionsLV-GLS is a robust predictor of cardiocerebrovascular outcomes in AIS and offers incremental prognostic value beyond traditional risk factors. Incorporating LV-GLS into AIS management may help identify high-risk patients and guide intensive monitoring strategies. REGISTRATION: URL: https://trialsearch.who.int. Unique identifier: KCT0005780.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.